News & Updates
Filter by Specialty:
Show Multimedia Only

Deucravacitinib delivers long-term efficacy in PsA
13 Oct 2025
byStephen Padilla
Treatment with deucravacitinib demonstrates its superiority to placebo across several endpoints in patients with psoriatic arthritis (PsA) at week 16, according to the phase III POETYK PsA-2 study. Clinical responses have also persisted for up to a year.